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Dear Editor,
W
e read with great interest the article entitled 
“The  Comparative  Efficacy  and  Safety 
of Peginterferon Alpha-2a vs. 2b for the Treatment 
of  Chronic  HCV  Infection:  A  Meta-Analysis”  by 
Alavian et al. (1). published in Hepatitis Monthly. In 
this article, the authors performed an elegant meta-
analysis of randomized controlled trials to compare 
the different effects (including efficacy and safety) 
of using two types of peginterferon, alpha-2a (PEG-
IFN-α2a) and 2b (PEG-IFN-α2b)  in the treatment 
of chronic hepatitis C virus (HCV) infection. By 
pooling data from 7 randomized controlled trials, 
the  authors  concluded  that  PEG-IFN-α2a  with 
similar safety is more effective than PEG-IFN-α2b; 
and  that  a  longer  duration  of  maximum  serum 
concentration compared with PEG-IFN-α2b yields 
a greater sustained virological response and higher 
neutropenia  in  PEG-IFN-α  2a  recipients.  These 
analysis  results  are  of  important  clinical  directive 
significance for using interferon alpha (IFN-α) to 
treat HCV-related liver diseases.
HCV  and  HBV  infections  are  major  global 
causes  of  liver-related  morbidity  and  mortality; 
and they are also the most common etiologies of 
hepatocellular carcinoma (HCC). However, IFN-α 
not  only  has  antiviral  activities  with  clearance  or 
suppression of HBV and HCV, but also possesses 
anti-tumor  properties  including  antiproliferative, 
antiangiogenic,  and  immunomodulatory  effects 
(2-4). In recent years, we and others have also done 
some excellent research work on this issue. In 2006 
(5),  we  performed  an  immunohistochemical  study 
of  P48  staining  on  specimens  that  were  collected 
from patients, in a randomized trial, who received 
postoperative IFN-a therapy (80 patients) and who 
did  not  receive  postoperative  IFN-a  therapy  (75 
patients); study results indicated that P48 was useful 
as a predictive marker of outcome after postoperative 
IFN-a treatment in patients with HBV-related HCC. 
Owing to the fact that the included subpopulation in 
our study consisted mostly of HBV-positive patients, 
whether our study results were suitable for HCV-
positive  patients  is  still  unknown;  so  our  further 
research may focus on this subpopulation.  
To the best of our knowledge, IFN-α has been 
widely used in the prevention and treatment of HCV 
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or HBV- related liver diseases (including hepatitis, 
cirrhosis,  HCC  etc.)  both  in  western  and  Asian 
countries;  it  alone  or  in  combination  with  other 
agents  might  offer  a  good  therapeutic  option  for 
patients with HCV or HBV-related liver diseases. 
Further explorations of the benefits of this use would 
be worthwhile.
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